Zacks Investment Research Downgrades Health Catalyst (NASDAQ:HCAT) to Hold

Zacks Investment Research lowered shares of Health Catalyst (NASDAQ:HCAT) from a buy rating to a hold rating in a research note published on Tuesday morning, Zacks.com reports.

According to Zacks, “Health Catalyst Inc. is a provider of data and analytics technology and services to healthcare organizations. Health Catalyst Inc. is based in Salt Lake City, Utah. “

HCAT has been the subject of a number of other reports. SVB Leerink reaffirmed a buy rating on shares of Health Catalyst in a research note on Sunday, September 26th. Jefferies Financial Group began coverage on Health Catalyst in a research note on Wednesday, December 1st. They set a hold rating and a $48.00 price target for the company. Citigroup decreased their price target on Health Catalyst from $68.00 to $55.00 and set a buy rating for the company in a research note on Monday, December 20th. Finally, BTIG Research assumed coverage on Health Catalyst in a research note on Thursday, October 14th. They set a buy rating and a $60.00 price objective for the company. Two analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of Buy and a consensus price target of $59.82.

Shares of HCAT stock opened at $32.06 on Tuesday. Health Catalyst has a 12-month low of $31.46 and a 12-month high of $59.50. The firm has a market capitalization of $1.67 billion, a price-to-earnings ratio of -9.77 and a beta of 0.71. The business has a 50 day simple moving average of $41.05 and a 200 day simple moving average of $49.06.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings results on Tuesday, November 9th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. The firm had revenue of $61.74 million during the quarter, compared to analyst estimates of $60.95 million. Health Catalyst had a negative return on equity of 22.56% and a negative net margin of 63.88%. During the same period last year, the company posted ($0.44) EPS. On average, sell-side analysts forecast that Health Catalyst will post -1.95 EPS for the current fiscal year.

In related news, insider Linda Llewelyn sold 3,300 shares of the stock in a transaction on Monday, November 1st. The stock was sold at an average price of $53.60, for a total transaction of $176,880.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Paul Horstmeier sold 10,750 shares of the stock in a transaction on Wednesday, January 5th. The stock was sold at an average price of $36.78, for a total value of $395,385.00. The disclosure for this sale can be found here. Insiders sold 114,012 shares of company stock valued at $4,757,532 in the last 90 days. Corporate insiders own 2.00% of the company’s stock.

Several large investors have recently made changes to their positions in the stock. BlackRock Inc. increased its position in Health Catalyst by 3.5% during the third quarter. BlackRock Inc. now owns 4,676,181 shares of the company’s stock worth $233,855,000 after buying an additional 156,525 shares during the last quarter. Vanguard Group Inc. increased its position in Health Catalyst by 17.8% during the second quarter. Vanguard Group Inc. now owns 3,502,231 shares of the company’s stock worth $194,409,000 after buying an additional 530,293 shares during the last quarter. Capital Research Global Investors increased its position in Health Catalyst by 0.9% during the third quarter. Capital Research Global Investors now owns 3,116,300 shares of the company’s stock worth $155,846,000 after buying an additional 27,083 shares during the last quarter. Alliancebernstein L.P. increased its position in Health Catalyst by 3.0% during the third quarter. Alliancebernstein L.P. now owns 2,188,095 shares of the company’s stock worth $109,427,000 after buying an additional 63,220 shares during the last quarter. Finally, Victory Capital Management Inc. increased its position in Health Catalyst by 38.8% during the third quarter. Victory Capital Management Inc. now owns 1,217,725 shares of the company’s stock worth $60,898,000 after buying an additional 340,087 shares during the last quarter.

About Health Catalyst

Health Catalyst, Inc engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology, and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers.

See Also: Treasury Bonds

Get a free copy of the Zacks research report on Health Catalyst (HCAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.